Philip Ashton-Rickardt

Insider Reports History

Entity
Individual
Location
C/O Sigilon Therapeutics, Inc., 100 Binney Street, Suite 600, Cambridge, MA
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Philip Ashton-Rickardt:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Sigilon Therapeutics, Inc. CHIEF SCIENTIFIC OFFICER Stock Option (Right to Buy) 0 $0.75 Aug 11, 2023 Direct

Insider Reports Filed by Philip Ashton-Rickardt

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SGTX Sigilon Therapeutics, Inc. Aug 11, 2023 1 -$6.63K 4 Aug 11, 2023 CHIEF SCIENTIFIC OFFICER
SGTX Sigilon Therapeutics, Inc. Feb 28, 2023 1 $0 4 Mar 1, 2023 CHIEF SCIENTIFIC OFFICER
SGTX Sigilon Therapeutics, Inc. Feb 18, 2022 1 $133K 4 Feb 22, 2022 CHIEF SCIENTIFIC OFFICER
SGTX Sigilon Therapeutics, Inc. Jan 3, 2022 1 $273K 4 Jan 4, 2022 CHIEF SCIENTIFIC OFFICER
SGTX Sigilon Therapeutics, Inc. Jul 1, 2021 1 $0 4 Jul 2, 2021 CHIEF SCIENTIFIC OFFICER
SGTX Sigilon Therapeutics, Inc. Jun 14, 2021 0 $0 3 Jun 14, 2021 Chief Scientific Officer